Ascendis Pharma (ASND) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ASND Stock Forecast

Ascendis Pharma stock forecast is as follows: an average price target of $190.21 (represents a 55.10% upside from ASND’s last price of $122.64) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.

ASND Price Target

The average price target for Ascendis Pharma (ASND) is $190.21 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $289.00 to $136.00. This represents a potential 55.10% upside from ASND's last price of $122.64.

ASND Analyst Ratings

Buy

According to 11 Wall Street analysts, Ascendis Pharma's rating consensus is 'Buy'. The analyst rating breakdown for ASND stock is 0 'Strong Buy' (0.00%), 10 'Buy' (90.91%), 1 'Hold' (9.09%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Ascendis Pharma Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 23, 2024	Tazeen Ahmad	Bank of America Securities	$191.00	$151.26	26.27%	55.74%
Sep 17, 2024	Gavin Clark-Gartner	Evercore ISI	$205.00	$144.97	41.41%	67.16%
Sep 17, 2024	Leland Gershell	Oppenheimer	$190.00	$143.90	32.04%	54.92%
Sep 17, 2024	David Lebowitz	Citigroup	$207.00	$139.57	48.31%	68.79%
Sep 17, 2024	Derek Archila	Wells Fargo	$289.00	$139.57	107.06%	135.65%
Sep 16, 2024	Tazeen Ahmad	Bank of America Securities	$175.00	$142.26	23.01%	42.69%
Sep 16, 2024	Paul Choi	Goldman Sachs	$200.00	$142.26	40.59%	63.08%
Sep 13, 2024	David Lebowitz	Citigroup	$178.00	$118.00	50.85%	45.14%
Sep 05, 2024	Leland Gershell	Oppenheimer	$180.00	$122.40	47.06%	46.77%
Aug 13, 2024	Kelly Shi	Jefferies	$196.00	$128.48	52.55%	59.82%

Row per page

Go to

The latest Ascendis Pharma stock forecast, released on Sep 23, 2024 by Tazeen Ahmad from Bank of America Securities, set a price target of $191.00, which represents a 26.27% increase from the stock price at the time of the forecast ($151.26), and a 55.74% increase from ASND last price ($122.64).

Ascendis Pharma Price Target by Period

	1M	3M	12M
# Anlaysts	-	9	13
Avg Price Target	-	$201.67	$195.54
Last Closing Price	$122.64	$122.64	$122.64
Upside/Downside	-100.00%	64.44%	59.44%

In the current month, the average price target of Ascendis Pharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Ascendis Pharma's last price of $122.64. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 21, 2024	Cowen & Co.	Buy	Buy	Hold
Sep 17, 2024	Evercore ISI	Outperform	Outperform	Hold
Sep 17, 2024	Oppenheimer	Outperform	Outperform	Hold
Sep 17, 2024	Wells Fargo	Overweight	Overweight	Hold
Sep 16, 2024	Bank of America Securities	Buy	Buy	Hold
Sep 16, 2024	Goldman Sachs	Buy	Buy	Hold
Sep 10, 2024	Citigroup	Buy	Buy	Hold
Sep 04, 2024	Cowen & Co.	Buy	Buy	Hold
Aug 13, 2024	Jefferies	Buy	Buy	Hold
Aug 12, 2024	Wells Fargo	Overweight	Overweight	Hold

Row per page

Go to

Ascendis Pharma's last stock rating was published by Cowen & Co. on Oct 21, 2024. The company gave ASND a "Buy" rating, the same as its previous rate.

Ascendis Pharma Financial Forecast

Ascendis Pharma Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$33.59M	$22.90M	$15.29M	$6.16M	$6.83M	$4.90M	$1.11M	$1.02M	$746.00K	$535.00K	$2.76M	$1.44M	$2.23M	$2.51M	$2.24M
Avg Forecast	$293.11M	$291.66M	$289.74M	$288.33M	$145.46M	$118.51M	$102.39M	$85.75M	$94.45M	$70.09M	$82.80M	$79.81M	$93.73M	$49.05M	$37.24M	$21.50M	$19.15M	$8.81M	$5.60M	$4.55M	$2.71M	$1.14M	$746.43K	$1.64M	$1.69M	$1.39M	$2.18M	$2.12M	$1.90M	$1.40M
High Forecast	$399.85M	$397.88M	$395.25M	$393.33M	$198.44M	$161.66M	$139.68M	$90.04M	$127.25M	$95.61M	$85.38M	$82.73M	$160.04M	$50.38M	$50.80M	$29.34M	$26.13M	$8.81M	$5.60M	$4.55M	$2.71M	$1.14M	$746.43K	$1.64M	$1.69M	$1.39M	$2.18M	$2.12M	$1.90M	$1.40M
Low Forecast	$243.30M	$242.10M	$240.50M	$239.33M	$120.74M	$98.37M	$84.99M	$81.45M	$70.73M	$58.18M	$80.23M	$76.89M	$61.23M	$47.72M	$30.91M	$17.85M	$15.90M	$8.81M	$5.60M	$4.55M	$2.71M	$1.14M	$746.43K	$1.64M	$1.69M	$1.39M	$2.18M	$2.12M	$1.90M	$1.40M
# Analysts	1	1	1	1	1	1	1	3	9	4	3	3	6	3	3	3	4	4	4	4	3	3	3	3	13	7	7	9	8	6
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.56%	1.20%	1.73%	1.10%	1.50%	1.81%	0.98%	1.37%	0.45%	0.32%	1.98%	0.66%	1.05%	1.32%	1.60%

Ascendis Pharma's average Quarter revenue forecast for Jun 23 based on 3 analysts is $37.24M, with a low forecast of $30.91M, and a high forecast of $50.80M. ASND's average Quarter revenue forecast represents a 10.86% increase compared to the company's last Quarter revenue of $33.59M (Mar 23).

Ascendis Pharma EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	9	4	3	3	6	3	3	3	4	4	4	4	3	3	3	3	13	7	7	9	8	6
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-95.23M	$-176.65M	$-123.36M	$-67.54M	$-115.44M	$-100.57M	$-75.68M	$-118.68M	$-58.40M	$-174.47M	$-79.52M	$-82.55M	$-60.95M	$-78.02M	$-22.89M
Avg Forecast	$-293.11M	$-291.66M	$-289.74M	$-288.33M	$-145.46M	$-118.51M	$-102.39M	$-85.75M	$-94.45M	$-70.09M	$-82.80M	$-79.81M	$-93.73M	$-49.05M	$-37.24M	$-21.50M	$-19.15M	$-8.81M	$-5.60M	$-93.33M	$-2.71M	$-1.14M	$-746.43K	$-65.11M	$-1.69M	$-1.39M	$-2.18M	$-57.26M	$-1.90M	$-1.40M
High Forecast	$-243.30M	$-242.10M	$-240.50M	$-239.33M	$-120.74M	$-98.37M	$-84.99M	$-81.45M	$-70.73M	$-58.18M	$-80.23M	$-76.89M	$-61.23M	$-47.72M	$-30.91M	$-17.85M	$-15.90M	$-8.81M	$-5.60M	$-74.66M	$-2.71M	$-1.14M	$-746.43K	$-52.09M	$-1.69M	$-1.39M	$-2.18M	$-45.81M	$-1.90M	$-1.40M
Low Forecast	$-399.85M	$-397.88M	$-395.25M	$-393.33M	$-198.44M	$-161.66M	$-139.68M	$-90.04M	$-127.25M	$-95.61M	$-85.38M	$-82.73M	$-160.04M	$-50.38M	$-50.80M	$-29.34M	$-26.13M	$-8.81M	$-5.60M	$-111.99M	$-2.71M	$-1.14M	$-746.43K	$-78.13M	$-1.69M	$-1.39M	$-2.18M	$-68.72M	$-1.90M	$-1.40M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.43%	9.22%	14.00%	12.07%	1.24%	37.10%	66.57%	159.00%	0.90%	103.20%	57.15%	37.87%	1.06%	41.09%	16.37%

undefined analysts predict ASND's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Ascendis Pharma's previous annual EBITDA (undefined) of $NaN.

Ascendis Pharma Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	9	4	3	3	6	3	3	3	4	4	4	4	3	3	3	3	13	7	7	9	8	6
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-110.91M	$-207.42M	$-168.96M	$-81.32M	$-125.50M	$-106.06M	$-80.35M	$-134.37M	$-62.79M	$-138.97M	$-121.74M	$-94.93M	$-63.32M	$-80.36M	$-25.11M
Avg Forecast	-	-	-	-	$-32.95M	$-51.09M	$-64.26M	$-77.19M	$-69.59M	$-89.44M	$-83.47M	$-85.03M	$-104.37M	$-136.40M	$-144.68M	$-151.90M	$-151.12M	$-146.33M	$-124.28M	$-101.46M	$-132.40M	$-131.89M	$-127.81M	$-70.00M	$-90.00M	$-90.16M	$-83.77M	$-59.48M	$-68.87M	$-68.44M
High Forecast	-	-	-	-	$-25.67M	$-39.80M	$-50.06M	$-67.12M	$-38.41M	$-69.68M	$-65.03M	$-66.25M	$-28.16M	$-106.26M	$-112.72M	$-118.34M	$-117.74M	$-146.33M	$-124.28M	$-81.17M	$-132.40M	$-131.89M	$-127.81M	$-56.00M	$-90.00M	$-90.16M	$-83.77M	$-47.59M	$-68.87M	$-68.44M
Low Forecast	-	-	-	-	$-48.55M	$-75.28M	$-94.68M	$-89.18M	$-84.96M	$-131.79M	$-122.99M	$-125.29M	$-212.63M	$-200.97M	$-213.17M	$-223.81M	$-222.67M	$-146.33M	$-124.28M	$-121.75M	$-132.40M	$-131.89M	$-127.81M	$-84.00M	$-90.00M	$-90.16M	$-83.77M	$-71.38M	$-68.87M	$-68.44M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.73%	1.37%	1.15%	0.65%	1.24%	0.80%	0.61%	1.05%	0.90%	1.54%	1.35%	1.13%	1.06%	1.17%	0.37%

Ascendis Pharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ASND's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Ascendis Pharma SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	9	4	3	3	6	3	3	3	4	4	4	4	3	3	3	3	13	7	7	9	8	6
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$66.54M	$56.55M	$60.67M	$56.58M	$47.42M	$48.30M	$39.28M	$35.34M	$37.25M	$20.43M	$17.52M	$20.80M	$17.91M	$17.08M	$10.00M
Avg Forecast	$2.38B	$2.37B	$2.35B	$2.34B	$1.18B	$961.30M	$830.61M	$695.56M	$766.16M	$568.54M	$671.70M	$647.41M	$760.29M	$397.90M	$302.05M	$174.44M	$155.35M	$71.49M	$45.39M	$36.88M	$21.99M	$9.22M	$6.05M	$13.32M	$13.71M	$11.29M	$17.68M	$17.20M	$15.40M	$11.34M
High Forecast	$3.24B	$3.23B	$3.21B	$3.19B	$1.61B	$1.31B	$1.13B	$730.39M	$1.03B	$775.59M	$692.60M	$671.11M	$1.30B	$408.71M	$412.06M	$237.97M	$211.93M	$71.49M	$45.39M	$36.88M	$21.99M	$9.22M	$6.05M	$13.32M	$13.71M	$11.29M	$17.68M	$17.20M	$15.40M	$11.34M
Low Forecast	$1.97B	$1.96B	$1.95B	$1.94B	$979.46M	$797.94M	$689.46M	$660.72M	$573.76M	$471.92M	$650.80M	$623.71M	$496.67M	$387.09M	$250.73M	$144.80M	$128.95M	$71.49M	$45.39M	$36.88M	$21.99M	$9.22M	$6.05M	$13.32M	$13.71M	$11.29M	$17.68M	$17.20M	$15.40M	$11.34M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.38%	0.36%	0.85%	1.25%	1.29%	2.20%	4.26%	5.84%	2.80%	1.49%	1.55%	1.18%	1.04%	1.11%	0.88%

Ascendis Pharma's average Quarter SG&A projection for Jun 23 is $302.05M, based on 3 Wall Street analysts, with a range of $250.73M to $412.06M. The forecast indicates a 353.95% rise compared to ASND last annual SG&A of $66.54M (Mar 23).

Ascendis Pharma EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	3	9	4	3	3	6	3	3	3	4	4	4	4	3	3	3	3	13	7	7	9	8	6
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-1.98	$-3.72	$-3.03	$-1.46	$-2.21	$-1.97	$-1.47	$-2.50	$-1.17	$-2.58	$-2.31	$-1.97	$-1.32	$-1.67	$-0.53
Avg Forecast	-	-	-	-	$-0.57	$-0.89	$-1.12	$-1.35	$-1.21	$-1.56	$-1.46	$-1.48	$-1.82	$-2.38	$-2.52	$-2.65	$-2.64	$-2.55	$-2.17	$-2.06	$-2.31	$-2.30	$-2.23	$-1.81	$-1.57	$-1.57	$-1.46	$-1.33	$-1.20	$-1.19
High Forecast	-	-	-	-	$-0.45	$-0.69	$-0.87	$-1.17	$-0.67	$-1.22	$-1.13	$-1.16	$-0.49	$-1.85	$-1.97	$-2.06	$-2.05	$-2.55	$-2.17	$-2.06	$-2.31	$-2.30	$-2.23	$-1.81	$-1.57	$-1.57	$-1.46	$-1.33	$-1.20	$-1.19
Low Forecast	-	-	-	-	$-0.85	$-1.31	$-1.65	$-1.56	$-1.48	$-2.30	$-2.14	$-2.18	$-3.71	$-3.50	$-3.72	$-3.90	$-3.88	$-2.55	$-2.17	$-2.06	$-2.31	$-2.30	$-2.23	$-1.81	$-1.57	$-1.57	$-1.46	$-1.33	$-1.20	$-1.19
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.75%	1.41%	1.19%	0.67%	1.07%	0.85%	0.64%	1.12%	0.65%	1.64%	1.47%	1.35%	0.99%	1.39%	0.44%

According to undefined Wall Street analysts, Ascendis Pharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ASND previous annual EPS of $NaN (undefined).

Ascendis Pharma Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
VTYX	Ventyx Biosciences	$1.73	$33.86	1857.23%	Buy
PLRX	Pliant Therapeutics	$12.85	$39.71	209.03%	Buy
DAWN	Day One Biopharmaceuticals	$13.34	$38.80	190.85%	Buy
STOK	Stoke Therapeutics	$11.27	$30.60	171.52%	Buy
APLS	Apellis Pharmaceuticals	$27.75	$74.50	168.47%	Buy
ETNB	89bio	$8.38	$22.00	162.53%	Buy
REPL	Replimune Group	$11.05	$24.20	119.00%	Buy
ASND	Ascendis Pharma	$122.64	$190.21	55.10%	Buy
AKRO	Akero Therapeutics	$31.20	$46.00	47.44%	Buy
BGNE	BeiGene	$194.56	$255.80	31.48%	Buy
AMLX	Amylyx Pharmaceuticals	$5.19	$6.67	28.52%	Buy
DICE	DICE Therapeutics	$47.55	$60.00	26.18%	Buy
CRNX	Crinetics Pharmaceuticals	$57.03	$70.14	22.99%	Buy
NUVL	Nuvalent	$92.73	$111.57	20.32%	Buy
BPMC	Blueprint Medicines	$96.62	$109.71	13.55%	Buy
UTHR	United Therapeutics	$367.36	$358.20	-2.49%	Buy
MDGL	Madrigal Pharmaceuticals	$329.24	$315.75	-4.10%	Buy
ACLX	Arcellx	$87.22	$83.00	-4.84%	Buy
KRTX	Karuna Therapeutics	$329.83	$257.50	-21.93%	Buy
KDNY	Chinook Therapeutics	$40.39	$30.00	-25.72%	Buy

ASND Forecast FAQ

Is Ascendis Pharma a good buy?

Yes, according to 11 Wall Street analysts, Ascendis Pharma (ASND) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 10 'Buy' recommendations, accounting for 90.91% of ASND's total ratings.

What is ASND's price target?

Ascendis Pharma (ASND) average price target is $190.21 with a range of $136 to $289, implying a 55.10% from its last price of $122.64. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Ascendis Pharma stock go up soon?

According to Wall Street analysts' prediction for ASND stock, the company can go up by 55.10% (from the last price of $122.64 to the average price target of $190.21), up by 135.65% based on the highest stock price target, and up by 10.89% based on the lowest stock price target.

Can Ascendis Pharma stock reach $200?

ASND's highest twelve months analyst stock price target of $289 supports the claim that Ascendis Pharma can reach $200 in the near future.

What are Ascendis Pharma's analysts' financial forecasts?

Ascendis Pharma's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $452.11M (high $589.83M, low $385.56M), average EBITDA is $-452M (high $-386M, low $-590M), average net income is $-225M (high $-183M, low $-308M), average SG&A $3.67B (high $4.78B, low $3.13B), and average EPS is $-3.932 (high $-3.185, low $-5.366). ASND's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.16B (high $1.59B, low $965.23M), average EBITDA is $-1.163B (high $-965M, low $-1.586B), average net income is $0 (high $0, low $0), average SG&A $9.43B (high $12.87B, low $7.83B), and average EPS is $0 (high $0, low $0).

Did the ASND's actual financial results beat the analysts' financial forecasts?

Based on Ascendis Pharma's last annual report (Dec 2022), the company's revenue was $51.17M, beating the average analysts forecast of $38.11M by 34.30%. Apple's EBITDA was $-527M, beating the average prediction of $-127M by 315.59%. The company's net income was $-583M, beating the average estimation of $-523M by 11.47%. Apple's SG&A was $221.23M, missing the average forecast of $309.1M by -28.43%. Lastly, the company's EPS was $-10.4, beating the average prediction of $-9.411 by 10.51%. In terms of the last quarterly report (Mar 2023), Ascendis Pharma's revenue was $33.59M, beating the average analysts' forecast of $21.5M by 56.20%. The company's EBITDA was $-95.231M, beating the average prediction of $-21.504M by 342.85%. Ascendis Pharma's net income was $-111M, missing the average estimation of $-152M by -26.98%. The company's SG&A was $66.54M, missing the average forecast of $174.44M by -61.86%. Lastly, the company's EPS was $-1.98, missing the average prediction of $-2.649 by -25.25%